Here are four things to know.
1. Novo Nordisk’s Xultophy and Sanofi’s Soliqua both combine long-acting insulin with a second type of medicine responsible for stimulating insulin production in the pancreas, according to the report.
2. Plainsboro, N.J.-based Novo Nordisk plans to launch Xultophy in the first half of 2017, taking extra me to negotiate reimbursement terms with insurers. Paris, France-based Sanofi plans to release Soliqua in January 2017.
3. Both drugmakers said the competing treatments will be sold at a lower price than the combined cost of the drugs’ ingredients, according to the report.
4. Industry analysts expect Xultophy to produce annual sales of about $1.20 billion in 2021 and predict Soliqua will only reach $550 million that same year, according to consensus estimates compiled by Thomson Reuters.
More articles on supply chain:
Gartner names top 25 supply chains in healthcare
More than two-thirds of hospital leaders expect to boost annual supply chain investment over next 3 years, survey finds
DHL Express will invest $185M in US operations to support increased shipping volumes: 3 takeaways
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
